Abstract:AbstractWe report a new in situ tissue slide‐based SELEX strategy targeting neoplastic tissues from breast cancer patients. The methodology, using the molecular differences between clinical specimens, can evolve aptamers to all fractions of tissue. The aptamers may be used as new molecular probes for pathological diagnosis and tumour imaging, and also to reveal the molecular differences that are responsible for the diseases. The specific aptamers were enriched by unequal length strand PCR employing a structured (−) strand primer. After 12 rounds of selection, using the paraffin tissue sections from infiltrating ductal carcinomas as targets, and using the adjacent normal tissue from the same case as controls, one of the enriched ssDNA aptamers, BC15, was selected from a nucleic acid library and characterized as recognizing breast cancer cells either within the tissue sections or from the culture medium, but only weakly binding to adjacent normal cells or immortalized breast cell line MCF10A. The calculated equilibrium dissociation constants (Kd) of BC15 bound to MCF7 cells was 111.0 ± 36.9 nM. Through streptavidin magnetic beads mediated affinity purification assay followed by mass spectrometry identification and western blot confirmation, the target of BC15 was characterized to be hnRNP A1, which was further verified to be specifically and highly expressed in cancerous tissues of breast by hnRNP A1 antibody immunostaining as well as western blot. BC15 aptamer was also used to probe cancer cells in tissues from other pathological types of breast cancers including lobular carcinoma, ductal carcinoma complicated with lobular carcinoma, comedo carcinoma, and lymph node metastasis of breast ductal carcinoma origin or breast lobular carcinoma origin. Therefore, tissue slide‐based SELEX holds promise in identifying tumour markers and developing specific molecular probes for cancer diagnosis. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Fluorescent quantum dot-labeled aptamer bioprobes specifically targeting mouse liver cancer cells.

[In-Vivo Targeted Imaging of Hepatocellular Carcinoma in Nude Mice Using Quantum Dot Probes].

Rapid Identification Of Specific Dna Aptamers Precisely Targeting Cd33 Positive Leukemia Cells Through A Paired Cell-Based Approach

Screening and application of aptamers as fluorescent biosensors for selective and sensitive detection of hepatocellular carcinoma and in vivo targeted delivery studies

The Biocompatibility of Quantum Dot Probes Used for the Targeted Imaging of Hepatocellular Carcinoma Metastasis.

Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.

Aptameric Fluorescent Biosensors for Liver Cancer Diagnosis

Technetium‐99m Radiolabeled Nucleolin-Targeted Aptamer for Glioma Tumor Imaging in Murine Models

Screening and Verification of Ssdna Aptamers Targeting Human Hepatocellular Carcinoma

Synthesis and application of a targeting diagnosis system via quantum dots coated by amphiphilic polymer for the detection of liver cancer cells

Highly fluorescent QD probes labeling hepatocellular carcinoma cells

Immuno-fluorescence imaging of hepatocellular carcinoma cells with quantum dots

In Vivo Fluorescence Imaging of Hepatocellular Carcinoma Using a Novel GPC3-specific Aptamer Probe

Quantum dot-labeled aptamer nanoprobes specifically targeting glioma cells.

SERS Nanoprobes in Biologically Raman Silent Region for Tumor Cell Imaging and in Vivo Tumor Spectral Detection in Mice

Cu-64-Labeled Aptamers For Tumor-Targeted Radionuclide Delivery

An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.

Dual-reporter fluorescent probe for precise identification of liver cancer by sequentially responding to carboxylesterase and polarity

A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma.

Identification of an aptamer targeting hnRNP A1 by tissue slide&hyphen;based SELEX

Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.